Pasithea Therapeutics Announces In Vivo Preclinical Efficacy Data For PAS-004 From NRAS Mutation Cancer Xenograft Models; Says Once Daily Dose Of PAS-004 Delivers Anti-Tumor Efficacy In In Vivo NRAS Mutation Cancer Models
Portfolio Pulse from Benzinga Newsdesk
Pasithea Therapeutics reported that its drug PAS-004 has shown anti-tumor efficacy in preclinical in vivo studies involving NRAS mutation cancer xenograft models. The drug was effective with a once-daily dose in these models.
December 11, 2023 | 1:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pasithea Therapeutics' announcement of positive preclinical efficacy data for PAS-004 in NRAS mutation cancer models may positively influence investor sentiment and the company's stock price in the short term.
Positive preclinical results often lead to increased investor confidence in a company's pipeline, potentially leading to stock price appreciation. As the direct developer of PAS-004, Pasithea Therapeutics stands to gain significantly if the drug continues to show promise, attracting investor interest and potentially funding for further development.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100